Effectiveness of Cryotherapy on the Fatigue of Patients With Multiple Sclerosis

NCT ID: NCT05219201

Last Updated: 2022-09-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

80 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-09-12

Study Completion Date

2027-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

the aim of the study is to evaluate the effectiveness of partial-body cryotherapy (PBC) on the symptoms of patients with multiple sclerosis during a rehabilitation stay.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Multiple sclerosis (MS) is a chronic heterogeneous disease with an unpredictable clinical course. Symptoms can include paralysis, ataxia, spasticity, incontinence and fatigue syndrome.

Fatigue is considered to be the most prevalent and disabling of the symptoms at all stages of the illness and its occurs in 70-80% of patients. This characteristic of the disease directly impacts the quality of life of patients, affecting their social and physical well being.

Physical rehabilitation is often prescribed in the management of MS, and is recognized to improve modifiable impairments in MS.

However, the benefit of physical activities may be limited by heat stress also named Uhthoff syndrome frequently observed in patients with MS.

Cryotherapy is commonly used as a method to relieve pain and inflammation without marked side effect in respect to contraindication. However well designed studies on PBC in patients with MS are still too sparse.

The investigators propose to evaluate the effectiveness of PBC on the symptoms of MS patients during a rehabilitation stay in out- or inpatients.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Multiple Sclerosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Sham cryotherapy full time patient (inpatient)

Patients benefiting from 15 session of "sham" partial-body cryotherapy session (-30°C) during their full-time rehabilitation stay

Group Type SHAM_COMPARATOR

partial-body cryotherapy chamber session

Intervention Type DEVICE

The cryotherapy procedure consisted of a 2-3 min stay in the cryotherapy chamber:

* at -30°C for sham cryotherapy session
* at -120°C for cryotherapy intervention session. For Inpatients, cryotherapy session will be performed daily, late in the afternoon, excluding saturdays and sundays, during 3 weeks. (15 sessions) For outpatient, cryotherapy session will occured late in the afternoon each day care (15 sessions).

sham cryotherapy part-time hospitalized patient (outpatient)

Patients benefiting from 15 session of "sham" partial-body cryotherapy session (-30°C) during their part-time rehabilitation stay

Group Type SHAM_COMPARATOR

partial-body cryotherapy chamber session

Intervention Type DEVICE

The cryotherapy procedure consisted of a 2-3 min stay in the cryotherapy chamber:

* at -30°C for sham cryotherapy session
* at -120°C for cryotherapy intervention session. For Inpatients, cryotherapy session will be performed daily, late in the afternoon, excluding saturdays and sundays, during 3 weeks. (15 sessions) For outpatient, cryotherapy session will occured late in the afternoon each day care (15 sessions).

cryotherapy full-time hospitalized patient (inpatient)

Patients benefiting from 15 session of "sham" partial-body cryotherapy session (-120°C) during their full-time rehabilitation stay

Group Type ACTIVE_COMPARATOR

partial-body cryotherapy chamber session

Intervention Type DEVICE

The cryotherapy procedure consisted of a 2-3 min stay in the cryotherapy chamber:

* at -30°C for sham cryotherapy session
* at -120°C for cryotherapy intervention session. For Inpatients, cryotherapy session will be performed daily, late in the afternoon, excluding saturdays and sundays, during 3 weeks. (15 sessions) For outpatient, cryotherapy session will occured late in the afternoon each day care (15 sessions).

cryotherapy part-time hospitalized patient (outpatient)

Patients benefiting from 15 session of "sham" partial-body cryotherapy session (-120°C) during their part-time rehabilitation stay

Group Type ACTIVE_COMPARATOR

partial-body cryotherapy chamber session

Intervention Type DEVICE

The cryotherapy procedure consisted of a 2-3 min stay in the cryotherapy chamber:

* at -30°C for sham cryotherapy session
* at -120°C for cryotherapy intervention session. For Inpatients, cryotherapy session will be performed daily, late in the afternoon, excluding saturdays and sundays, during 3 weeks. (15 sessions) For outpatient, cryotherapy session will occured late in the afternoon each day care (15 sessions).

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

partial-body cryotherapy chamber session

The cryotherapy procedure consisted of a 2-3 min stay in the cryotherapy chamber:

* at -30°C for sham cryotherapy session
* at -120°C for cryotherapy intervention session. For Inpatients, cryotherapy session will be performed daily, late in the afternoon, excluding saturdays and sundays, during 3 weeks. (15 sessions) For outpatient, cryotherapy session will occured late in the afternoon each day care (15 sessions).

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

CRYO00002 ICE X- Cryosauna local cryotherapy devices DM Class IIb

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* men and woen over 18 years old and under 65 years old
* with multiple sclerosis
* 0-6 points in the expanded disability states scale (EDSS)
* with MS in remission (at least 6 months since the last relapse)
* able to understand and respect the protocol and its requirement
* who signed the consent prior to any other procedure protocol

Exclusion Criteria

* major patients under guardianship/curators/legal protection
* pregnant patients
* patients with contraindication for cryotherapy
* patients unable to complete the entire program
* patients with substantial change in pharmacological treatment the month before the start of the study
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Lille Catholic University

OTHER

Sponsor Role collaborator

Fondation Ildys

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Jean-Baptiste Bourseul, MD

Role: PRINCIPAL_INVESTIGATOR

Fondation Ildys

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Centre de Perharidy

Roscoff, , France

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Matthieu Pichelin

Role: CONTACT

02.98.02.85.00

Marion Buyse, PhD, PharmD

Role: CONTACT

0298293447

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Jocelyne PENGAM

Role: primary

Morgane AUFFRET

Role: backup

References

Explore related publications, articles, or registry entries linked to this study.

Pawik M, Kowalska J, Rymaszewska J. The effectiveness of whole-body cryotherapy and physical exercises on the psychological well-being of patients with multiple sclerosis: A comparative analysis. Adv Clin Exp Med. 2019 Nov;28(11):1477-1483. doi: 10.17219/acem/104529.

Reference Type BACKGROUND
PMID: 30968613 (View on PubMed)

Bouzigon R, Grappe F, Ravier G, Dugue B. Whole- and partial-body cryostimulation/cryotherapy: Current technologies and practical applications. J Therm Biol. 2016 Oct;61:67-81. doi: 10.1016/j.jtherbio.2016.08.009. Epub 2016 Aug 27.

Reference Type BACKGROUND
PMID: 27712663 (View on PubMed)

Radecka A, Knyszynska A, Luczak J, Lubkowska A. Adaptive changes in muscle activity after cryotherapy treatment: Potential mechanism for improvement the functional state in patients with multiple sclerosis. NeuroRehabilitation. 2021;48(1):119-131. doi: 10.3233/NRE-201535.

Reference Type BACKGROUND
PMID: 33386821 (View on PubMed)

Zielinska-Nowak E, Wlodarczyk L, Kostka J, Miller E. New Strategies for Rehabilitation and Pharmacological Treatment of Fatigue Syndrome in Multiple Sclerosis. J Clin Med. 2020 Nov 7;9(11):3592. doi: 10.3390/jcm9113592.

Reference Type BACKGROUND
PMID: 33171768 (View on PubMed)

Miller E, Kostka J, Wlodarczyk T, Dugue B. Whole-body cryostimulation (cryotherapy) provides benefits for fatigue and functional status in multiple sclerosis patients. A case-control study. Acta Neurol Scand. 2016 Dec;134(6):420-426. doi: 10.1111/ane.12557. Epub 2016 Jan 18.

Reference Type BACKGROUND
PMID: 26778452 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

ID-RCB 2021-A02526-35

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

MS Spinal Mobilisation Study
NCT05090709 COMPLETED NA
Non-Invasive Stimulation for Improving Motor Function
NCT03592173 ACTIVE_NOT_RECRUITING PHASE2